260 related articles for article (PubMed ID: 10081854)
1. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
Rajala P; Liukkonen T; Raitanen M; Rintala E; Kaasinen E; Helle M; Lukkarinen O
J Urol; 1999 Apr; 161(4):1133-5; discussion 1135-6. PubMed ID: 10081854
[TBL] [Abstract][Full Text] [Related]
2. Perioperative single dose instillation of epirubicin or interferon-alpha after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study--FinnBladder III long-term results.
Rajala P; Kaasinen E; Raitanen M; Liukkonen T; Rintala E;
J Urol; 2002 Sep; 168(3):981-5. PubMed ID: 12187204
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
4. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Raitanen MP; Lukkarinen O
Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
[TBL] [Abstract][Full Text] [Related]
5. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
6. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
[TBL] [Abstract][Full Text] [Related]
7. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
8. Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma.
Kaasinen E; Rintala E; Pere AK; Kallio J; Puolakka VM; Liukkonen T; Tuhkanen K
J Urol; 2000 Jul; 164(1):47-52. PubMed ID: 10840422
[TBL] [Abstract][Full Text] [Related]
9. Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study.
Ali-el-Dein B; Nabeeh A; el-Baz M; Shamaa S; Ashamallah A
Br J Urol; 1997 May; 79(5):731-5. PubMed ID: 9158511
[TBL] [Abstract][Full Text] [Related]
10. A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder.
Oosterlinck W; Kurth KH; Schröder F; Bultinck J; Hammond B; Sylvester R
J Urol; 1993 Apr; 149(4):749-52. PubMed ID: 8455236
[TBL] [Abstract][Full Text] [Related]
11. Interferon-a2b reduces neo-microvascular density in the 'normal' urothelium adjacent to the tumor after transurethral resection of superficial bladder carcinoma.
Giannopoulos A; Adamakis I; Evangelou K; Giannopoulou M; Zacharatos P; Zsantoulis P; Perunovic B; Athanasiou A; Retalis G; Constandinidis C; Gorgoulis VG
Onkologie; 2003 Apr; 26(2):147-52. PubMed ID: 12771523
[TBL] [Abstract][Full Text] [Related]
12. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
Divrik RT; Yildirim U; Zorlu F; Ozen H
J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
[TBL] [Abstract][Full Text] [Related]
13. Role of interferon-alpha-2b in the prevention of superficial carcinoma of the bladder recurrence.
Mohanty NK; Gulati P; Saxena S
Urol Int; 1997; 59(3):194-6. PubMed ID: 9428441
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
[TBL] [Abstract][Full Text] [Related]
15. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
Serretta V; Piazza S; Pavone C; Piazza B; Pavone-Macaluso M
Urology; 1996 May; 47(5):647-51. PubMed ID: 8650860
[TBL] [Abstract][Full Text] [Related]
16. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
17. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?
Altay B; Girgin C; Kefi A; Cikili N
Int Urol Nephrol; 2000; 32(1):53-8. PubMed ID: 11057773
[TBL] [Abstract][Full Text] [Related]
18. Bacillus Calmette-Guérin is superior to a combination of epirubicin and interferon-alpha2b in the intravesical treatment of patients with stage T1 urinary bladder cancer. A prospective, randomized, Nordic study.
Duchek M; Johansson R; Jahnson S; Mestad O; Hellström P; Hellsten S; Malmström PU;
Eur Urol; 2010 Jan; 57(1):25-31. PubMed ID: 19819617
[TBL] [Abstract][Full Text] [Related]
19. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
Tzai TS; Chow NH; Lin JS; Yang WH; Tong YC
Anticancer Res; 1998; 18(6B):4717-21. PubMed ID: 9891547
[TBL] [Abstract][Full Text] [Related]
20. Prospective phase II trial of alternating intravesical Bacillus Calmette-Guérin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results.
Bazarbashi S; Raja MA; El Sayed A; Ezzat A; Ibrahim E; Kattan S; Kardar A; Peracha A; Lindstedt E; Hanash K
J Surg Oncol; 2000 Jul; 74(3):181-4. PubMed ID: 10951412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
